Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703426 | 0.86 | PIK3CD (0.47) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL1703546 | 0.85 | ALDH1A1 (0.57) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL1703448 | 0.81 | POLB (0.51) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL754924 | 0.80 | PIK3CD (0.60) | PIK3CDPDE7AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL16583419 | 0.80 | PIK3CD (0.60) | PIK3CDPDE7AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1703433 | 0.80 | ALDH1A1 (0.44) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL6222959 | 0.79 | ALDH1A1 (0.63) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL7509337 | 0.78 | PIK3CD (0.44) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL1703684 | 0.77 | ALDH1A1 (0.43) | PIK3CDPDE7APDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL16583546 | 0.76 | PIK3CD (0.50) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-2097422-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | Eli Lilly & Co. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PDE7A 2724/4885PDE4B 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.